Corrigendum to “Preclinical evaluation of the safety and effectiveness of a new bioartificial cornea” [Bioact. Mater. 2023 (8) 29 265–278]

Abstract

Cross-linking agents are frequently used to restore corneal properties after decellularization, and it is especially important to select an appropriate method to avoid excessive cross-linking. In addition, how to promote wound healing and how to improve scar formation require further investigation. To ensure the safety and efficacy of animal-derived products, we designed bioartificial corneas (BACs) according to the criteria for Class III medical devices. Our BACs do not require cross-linking agents and increase mechanical strength via self-cross-linking of aldehyde-modified hyaluronic acid (AHA) and carboxymethyl chitosan (CMC) on the surface of decellularized porcine corneas (DPCs). The results showed that the BACs had good biocompatibility and transparency, and the modification enhanced their antibacterial and anti-inflammatory properties in vitro. Preclinical animal studies showed that the BACs can rapidly regenerate the epithelium and restore vision within a month. After 3 months, the BACs were gradually filled with epithelial, stromal, and neuronal cells, and after 6 months, their transparency and histology were almost normal. In addition, side effects such as corneal neovascularization, conjunctival hyperemia, and ciliary body hyperemia rarely occur in vivo. Therefore, these BACs show promise for clinical application for the treatment of infectious corneal ulcers and as a temporary covering for corneal perforations to achieve the more time.

The authors regret that two images (Control and 1m) in Fig. 3B were originally repeat placement by a careless mistake. The original and corrected versions of these images are provided below. These corrections do not alter any findings and conclusions reported in this article. No additional text corrections are needed in the article.

Fig. 3.

Original and revised figure of Fig. 3B(1m)

The authors would like to apologise for any inconvenience caused.

CRediT authorship contribution statement

Yansha Hao: Formal analysis, Methodology, Writing – original draft, Writing – review & editing. Jingting Zhou: Formal analysis, Methodology, Writing – original draft. Ju Tan: Formal analysis, Methodology, Writing – original draft. Lingqin Zeng: Writing – original draft, Methodology. Gang Li: Methodology, Formal analysis. Mingcan Yang: Methodology, Formal analysis. Wen Zeng: Funding acquisition, Methodology, Investigation. Chuhong Zhu: Funding acquisition, Conceptualization, Supervision, Writing – review & editing.

Declaration of competing interest

The authors declare the following personal relationships which may be considered as potential competing interests: Jun Yao is currently employed by Hong Chang Biotechnology Co., Ltd.